Walgreens Specialty Pharmacy

Overview

Walgreens Specialty Pharmacy is the current Walgreens specialty platform - the active brand for buyers who may still search AllianceRx Walgreens Pharmacy, AllianceRx Walgreens Prime, or Walgreens AllianceRx. Walgreens Boots Alliance went private under Sycamore Partners in 2025; the specialty arm continues to operate as the largest PBM-neutral national specialty pharmacy, with a 265-product LDD network, nearly 300 million covered lives, more than 260 specialty pharmacy locations, central specialty infrastructure, community pharmacy access, and a distinct Walgreens Hub Solutions surface for manufacturer patient support.

Walgreens Specialty is NOT a PBM-owned specialty pharmacy, an oncology-only operation, a rare-disease boutique, or a PBM-integrated hub. It is most useful when a brand needs neutral specialty pharmacy distribution at scale for limited distribution, community access, clinical support, patient affordability / adherence workflows, and hub-adjacent manufacturer support. PBM-owned peers may be stronger when the launch depends on captive specialty routing, payer-data integration, formulary adjacency, or PBM benefit-design influence.

Specialty Pharmacy Capability Model

The framework below standardizes how Rx Almanac evaluates specialty-pharmacies capabilities, so buyers can compare vendors like-for-like while the readout column stays vendor-specific. For this table, Walgreens Specialty Pharmacy is evaluated as current Walgreens specialty platform - the active brand for buyers who may still search AllianceRx Walgreens Pharmacy, AllianceRx Walgreens Prime, or Walgreens AllianceRx.

Capability	Buyer should compare	Walgreens Specialty Pharmacy readout
Specialty dispensing and channel access	Licensed dispensing footprint, payer network access, LDD participation, referral capture, and ability to serve the target patient geography.	Major fulfillment handoff. Walgreens Specialty Pharmacy combines central specialty infrastructure, 260+ specialty locations, community pharmacy access, and a 265-product LDD network.
Benefits, PA, and reimbursement support	Benefit investigation, PA support, appeals coordination, copay/PAP routing, and reimbursement troubleshooting at the pharmacy edge.	Core diligence area. Walgreens Hub Solutions describes integrated portals, e-prescribing, immediate engagement, BI, insurance authorization, financial assistance, and hub handoffs; validate therapy-specific rules.
Clinical therapy management and adherence	Pharmacist counseling, disease-specific protocols, refill outreach, injection training, persistence programs, and clinical escalation.	Engagement model. Enterprise Specialty / Specialty 360 materials emphasize in-house pharmacists and nurses with disease-state expertise, provider engagement, handling guidance, adherence barriers, and ongoing treatment support.
Cold chain, REMS, and complex handling	Temperature control, REMS certification, hazardous/controlled-substance handling, biologics, CGT, and other special distribution requirements.	Accreditation-supported. Walgreens has current NABP and URAC specialty accreditation activity plus ACHC gene / cell and central specialty / infusion accreditation credentials.
Manufacturer data and outcomes reporting	Status feeds, dispense data, adherence/outcomes reporting, inventory visibility, and reporting cadence suitable for launch governance.	Contract-sensitive. Walgreens materials highlight enhanced reporting, portals, and real-time access; define fields, cadence, suppression thresholds, and abandonment / conversion definitions.
Site-of-care, infusion, or health-system coordination	Home infusion, ambulatory infusion, provider-office coordination, health-system capture, and buy-and-bill support where relevant.	Adjacent capability. Specialty 360 highlights local specialty pharmacists with health-system / site-of-care relationships; ACHC central specialty / infusion credentials still need product-specific validation.

Buyer Fit

• Evaluation trigger: Include Walgreens Specialty when a national specialty launch needs PBM-neutral distribution at scale with broad covered-life reach, 260+ specialty locations, 265-product LDD participation, community pharmacy access, and accreditation credentials across NABP, URAC, ACHC gene / cell, and central specialty / infusion.
• Profile signal: Largest PBM-neutral national specialty pharmacy; 260+ specialty locations; 265 LDD products; nearly 300M covered lives; current NABP, URAC v5.0, ACHC Gene & Cell, and ACHC central specialty / infusion accreditations under Sycamore Partners ownership.
• Best-fit therapies: Oncology, immunology, neurology, rare disease, infectious disease, respiratory, hematology, and CGT launches that need neutral national distribution plus community pharmacy access.
• Less ideal fit: Products that need PBM-owned routing power, formulary adjacency, integrated payer / claims data, or rare-disease boutique intimacy; programs that expect PBM-style data depth from a PBM-neutral pharmacy.
• Commercial fit: Pricing is undisclosed; assume RFP-led scope with service levels, central vs community specialty split, data feeds, and Sycamore-era continuity commitments defined in the SOW.
• Network diligence: LDD eligibility for the specific product, payer-network access without captive PBM routing, Hub Solutions scope, accreditation applicability, manufacturer reporting cadence, and how Sycamore ownership, store closures, staffing, or restructuring could affect service levels.

Differentiators

• PBM-neutral scale: Walgreens is the scaled national alternative when a manufacturer wants broad specialty pharmacy reach without using a PBM-owned SP as the primary channel.
• LDD footprint: Walgreens reported 265 limited-distribution-drug products, including 2025 additions across HIV prevention, dermatology, and oncology.
• Specialty site and Hub Solutions surface: Walgreens now routes manufacturer-facing specialty pharmacy through walgreensspecialtyrx.com, /pharma/, and walgreenshubsolutions.com, separating core specialty, pharma, and hub-services workflows.
• Company-reported operating metrics: Current Walgreens materials cite 260+ specialty locations, 94% adherence from 2024 central specialty data, 48-hour average fulfillment time, and 96% 2025 patient satisfaction; use these as RFP benchmarks.
• Enterprise Specialty / Specialty 360: In-house pharmacists and nurses, provider engagement representatives, local specialty pharmacists, proprietary clinical management, and enhanced reporting add manufacturer-facing detail beyond generic dispensing.
• Accreditation stack: Walgreens has current company materials around NABP specialty reaccreditation, URAC Specialty Pharmacy v5.0 accreditation, ACHC Gene and Cell Services, and central specialty / infusion accreditation credentials.
• Community access: The Walgreens pharmacy footprint can support patient education, adherence, affordability navigation, and local specialty handoffs where product rules allow.
• Advanced therapy relevance: Gene / cell and infusion credentials make Walgreens worth evaluating for complex therapies, but the actual service model should be validated product by product.

RFP Questions

• Which LDD products, payer networks, REMS programs, and disease-state protocols can Walgreens support for this launch?
• What portion of expected volume will run through central specialty, community specialty, retail handoffs, or external partners?
• Which NABP, URAC, ACHC specialty, ACHC gene / cell, or ACHC infusion credentials apply directly to the proposed service line?
• What therapy-specific workflow will Walgreens provide across enrollment, BI, PA, appeals, affordability, dispensing, refill, adherence, and escalation?
• What metrics are guaranteed: time to first fill, PA approval / denial, abandonment, average patient OOP, persistence, adherence, patient satisfaction, and prescriber satisfaction?
• What data fields, cadence, ownership rights, and reconciliation process will govern manufacturer reporting?
• Which Walgreens Hub Solutions portals, e-prescribing, BI, authorization, financial-assistance, free-goods, commercial-dispense, provider, field-reimbursement, and patient workflows are included?
• How will Walgreens handle payer / PBM barriers without the same captive PBM routing and claims-data access as PBM-owned specialty pharmacies?

Recent Activity

• 2026: Walgreens Specialty Pharmacy earned NABP Specialty Pharmacy reaccreditation through August 2028.
• 2026: Walgreens Specialty Pharmacy received URAC Specialty Pharmacy v5.0 accreditation effective January 2026 through January 2029.
• 2026: Walgreens’ current specialty, pharma, and Hub Solutions sites surfaced 260+ specialty locations, Enterprise Specialty / Specialty 360, enhanced reporting, provider engagement, and company-reported adherence / fulfillment / satisfaction benchmarks.
• 2025: Walgreens Specialty Pharmacy expanded its LDD network to 265 products.
• 2025: Walgreens Specialty Pharmacy received ACHC Gene and Cell Services accreditation; Walgreens Central Specialty Pharmacy also received ACHC central specialty / infusion accreditations and specialty-pharmacy reaccreditation with oncology, rare-disease, and orphan-drug distinctions.
• 2025: Sycamore Partners completed the Walgreens take-private, making ownership and service-continuity diligence more important for large manufacturer programs.